首页> 外文期刊>Biochimica et biophysica acta. Biomembranes >Amyloid beta ion channel: 3D structure and relevance to amyloid channel paradigm
【24h】

Amyloid beta ion channel: 3D structure and relevance to amyloid channel paradigm

机译:淀粉样β离子通道:3D结构及其与淀粉样通道范式的相关性

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Alzheimer's disease (AD) is a protein misfolding disease. Early hypothesis of AD pathology posits that 39-43 AA long misfolded amyloid beta (Aβ) peptide forms a fibrillar structure and induces pathophysiological response by destabilizing cellular ionic homeostasis. Loss of cell ionic homeostasis is believed to be either indirectly due to amyloid beta-induced oxidative stress or directly by its interaction with the cell membrane and/or activating pathways for ion exchange. Significantly though, no Aβ specific cell membrane receptors are known and oxidative stress mediated pathology is only partial and indirect. Most importantly, recent studies strongly indicate that amyloid fibrils may not by themselves cause AD pathology. Subsequently, a competing hypothesis has been proposed wherein amyloid derived diffusible ligands (ADDLs) that are large Aβ oligomers (~> 60 kDa), mediate AD pathology. No structural details, however, of these large globular units exist nor is there any known suitable mechanism by which they would induce AD pathology. Experimental data indicate that they alter cell viability by non-specifically changing the plasma membrane stability and increasing the overall ionic leakiness. The relevance of this non-specific mechanism for AD-specific pathology seems limited. Here, we provide a viable new paradigm: AD pathology mediated by amyloid ion channels made of small Aβ oligomers (trimers to octamers). This review is focused to 3D structural analysis of the Aβ channel. The presence of amyloid channels is consistent with electrophysiological and cell biology studies summarized in companion reviews in this special issue. They show ion channel-like activity and channel-mediated cell toxicity. Amyloid ion channels with defined gating and pharmacological agents would provide a tangible target for designing therapeutics for AD pathology.
机译:阿尔茨海默氏病(AD)是一种蛋白质错误折叠疾病。 AD病理学的早期假设认为,39-43 AA长错折叠的淀粉样蛋白β(Aβ)肽形成原纤维结构,并通过破坏细胞离子稳态而诱导病理生理反应。据信细胞离子稳态的丧失是由于β淀粉样蛋白诱导的氧化应激间接引起的,或直接由于其与细胞膜的相互作用和/或离子交换的活化途径而引起的。但是,重要的是,尚无Aβ特异性细胞膜受体,氧化应激介导的病理仅是部分和间接的。最重要的是,最近的研究强烈表明淀粉样蛋白原纤维本身可能不会引起AD病理。随后,提出了一个竞争性假设,其中淀粉状蛋白衍生的可扩散配体(ADDLs)是大的Aβ低聚物(〜> 60 kDa)介导AD病理。但是,不存在这些大球状单位的结构细节,也没有任何已知的合适机制可通过它们诱发AD病理。实验数据表明,它们通过非特异性改变质膜稳定性并增加总体离子泄漏来改变细胞活力。这种非特定机制与AD特定病理学的相关性似乎有限。在这里,我们提供了一种可行的新范例:由小Aβ低聚物(三聚体到八聚体)构成的淀粉样蛋白离子通道介导的AD病理。本文的重点是Aβ通道的3D结构分析。淀粉样蛋白通道的存在与本期特刊的同行评述中总结的电生理学和细胞生物学研究一致。它们显示出离子通道样活性和通道介导的细胞毒性。具有确定的门控和药理学作用的淀粉样蛋白离子通道将为设计用于AD病理学的疗法提供切实的目标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号